Chronic kidney disease stages 3 to 5 with chronic hyperkalemia Hyperkalemia Kidney Diseases, Chronic Diuretics, Thiazide Sodium Zirconium Cyclosilicate Polystyrenes Potassium
Conditions
Interventions
Participants in the SZC group will receive sodium zirconium cyclosilicate 5 grams once daily orally after breakfast for 14 days. Dose may be adjusted on day 7 based on serum potassium.,Participants in
Sodium Zirconium Cyclosilicate ,Calcium polystyrene sulfonate ,Hydrochlorothiazide
Sponsors
Ratchadapisek Research Funds (Type I)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age 18 years or older 2.Diagnosed with chronic kidney disease stage 3 to 5 with eGFR less than 60 mL per min per 1 point 73 square meter 3.Serum potassium between 4 point 8 and 5 point 9 mmol per liter 4.Serum bicarbonate between 18 and 24 mmol per liter 5.No use of diuretics or calcium polystyrene sulfonate within 14 days before enrollment
Exclusion criteria
Exclusion criteria: 1.On hemodialysis or peritoneal dialysis 2.Kidney transplant recipient 3.Active gastrointestinal infection 4.Serum potassium greater than 6 mmol per liter 5.Electrocardiogram with significant abnormalities such as peaked T waves or wide QRS 6.Heart rate less than 60 or greater than 150 beats per minute 7.Systolic blood pressure less than 90 mmHg or diastolic blood pressure less than 60 mmHg 8.Active malignancy 9.Pregnancy 10.History of severe allergy to study medications 11.Serum uric acid greater than 13 mg per dL 12.Acute gout attack 13.Suspected pseudohyperkalemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in serum potassium level from baseline to day 7 7 days after treament mmol/L | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum potassium level from baseline to day 14 14 days after treatment mmol/L,Proportion of participants achieving normal serum potassium at day 7 7 days after treatment percentage,Proportion of participants achieving normal serum potassium at day 14 14 days after treatment percentage,Change in serum bicarbonate level from baseline to day 7 7 days after treatment meq/L,Change in serum bicarbonate level from baseline to day 14 14 days after treatment meq/L,Change in gastrointestinal symptoms assessed by GSRS from baseline to day 7 7 days after treatment 7 points likert scale,Change in gastrointestinal symptoms assessed by GSRS from baseline to day 14 14 days after treatment 7 points likert scale,Incidence of adverse events up to day 14 14 days after treatment Number and type of adverse events reported by participants or observed by investigators. | — |
Countries
Thailand
Contacts
Public ContactJathurong Kittrakulrat
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed